BRUIN-MCL-321: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Study Details
Study Description
Brief Summary
This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
This is a Phase 3 global, randomized, open-label study comparing pirtobrutinib (Arm A) to investigator's choice of ibrutinib, acalabrutinib or zanubrutinib (Arm B) in MCL patients who have received 1 or more lines of therapy and are BTK inhibitor naïve.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Arm A (Pirtobrutinib) Orally |
Drug: Pirtobrutinib
Oral
Other Names:
|
Active Comparator: Arm B (Ibrutinib, Acalabrutinib, or Zanubrutinib) Investigator's choice (based on local availability) of ibrutinib, acalabrutinib or zanubrutinib orally. Options are limited to those that are available/approved in the specific country. |
Drug: Ibrutinib
Oral
Other Names:
Drug: Acalabrutinib
Oral
Other Names:
Drug: Zanubrutinib
Oral
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL) [Up to approximately 24 months]
Assessed per Lugano criteria
Secondary Outcome Measures
- To compare Event Free Survival (EFS) as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment arms [Up to approximately 24 months]
Defined as the time from randomization to progressive disease (PD) or start of new treatment for MCL or withdrawal from trial due to toxicity or death
- To compare Time to Treatment Failure (TTTF) as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment arms [Up to approximately 24 months]
Time from randomization to time when discontinuation criteria met
- Time to worsening (TTW) of MCL-related symptoms [Up to approximately 24 months]
Using symptom questions identified from the European Organization for Research and Treatment of Cancer (EORTC) item library. The range of raw scores for these items could be from 0 to 52 with highest score being worse symptoms.
- Comparative Tolerability as measured by proportion of time with high side effect burden [Up to approximately 24 months]
Using 18 items covering 10 Patient Reported Outcome- Common Terminology Criteria for Adverse Events (PRO-CTCAE) concepts for frequency (0-5 with 5 as most frequent), and/or presence (0-1 with 1 being present), or Severity (0-5 with 5 as most severe) and/or presence (0-1 with 1 being present); these selective adverse events will be framed and then overall side effect burden will be ascertained with the Functional Assessment of Cancer Therapy (FACT) - Item GP5. The range of this item is 0 -4 with 4 as most bothersome.
- To compare Overall Response Rate (ORR) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment arms [Up to approximately 24 months]
Assessed per Lugano criteria
- To compare Duration of Response (DOR) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment arms [Up to approximately 24 months]
Assessed per Lugano criteria
- To compare Overall Survival of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment arms [Up to approximately 24 months]
Assessed by survival
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Confirmed MCL diagnosis
-
Previously treated with at least one prior line of systemic therapy for MCL
-
Measurable disease per Lugano criteria
-
Eastern Cooperative Oncology Group (ECOG) 0-2
-
Absolute neutrophil count ≥ 0.75 × 109/L without granulocyte-colony stimulating factor support within 7 days of screening
-
Hemoglobin ≥ 8 g/dL not requiring transfusion support or growth factors within 7 days of screening
-
Platelets ≥ 50 × 109/L not requiring transfusion support or growth factors within 7 days of screening.
-
AST and ALT ≤ 3.0 x upper limit of normal (ULN).
-
Total bilirubin ≤ 1.5 x ULN.
-
Creatinine clearance of ≥ 30 mL/min according to Cockcroft/Gault Formula
Exclusion Criteria:
-
Prior treatment with an approved or investigational BTK inhibitor
-
History of bleeding diathesis
-
History of stroke or intracranial hemorrhage within 6 months of randomization
-
History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor modified T-cell (CAR-T) therapy within 60 days of randomization
-
Clinically significant cardiovascular disease
-
Prolonged QT interval corrected using Fridericia's formula (QTcF) > 470 ms on 2/3 consecutive ECGs, and mean QTcF>470 ms on all 3 ECGs
-
Known HIV infection or active HBV, HCV, or CMV infections
-
Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption
-
Ongoing chronic treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers which cannot be stopped within 3-5 half lives of the CYP3A inhibitor therapy prior to start of study drug treatment.
-
Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.
-
Vaccination with live vaccine within 28 days prior to randomization
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Arizona Oncology Associates, P.C. - HOPE | Phoenix | Arizona | United States | 85016 |
2 | Arizona Oncology Associates, P.C. - HOPE | Tucson | Arizona | United States | 85711 |
3 | St. Joseph Heritage Healthcare | Fullerton | California | United States | 92835 |
4 | The Oncology Institute of Hope and Innovation | Long Beach | California | United States | 90805 |
5 | Rocky Mountain Cancer Center | Aurora | Colorado | United States | 80012 |
6 | Medical Oncology Hematology Consultants, PA | Newark | Delaware | United States | 19713 |
7 | Florida Cancer Specialists | Fort Myers | Florida | United States | 33901 |
8 | Mayo Clinic in Florida | Jacksonville | Florida | United States | 32224 |
9 | Florida Cancer Specialists | Saint Petersburg | Florida | United States | 33705 |
10 | Florida Cancer Specialists | Tallahassee | Florida | United States | 32308 |
11 | Florida Cancer Specialists East | West Palm Beach | Florida | United States | 33401 |
12 | University of Kentucky Markey Cancer Center | Lexington | Kentucky | United States | 40504 |
13 | Mercy Health-Paducah Medical Oncology and Hematology | Paducah | Kentucky | United States | 42003 |
14 | Hematology Oncology Clinic | Baton Rouge | Louisiana | United States | 70809 |
15 | Cancer Center Office of Clinical Research | New Orleans | Louisiana | United States | 70112 |
16 | Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | United States | 21201 |
17 | University of Michigan | Ann Arbor | Michigan | United States | 48109 |
18 | Karmanos Cancer Institute | Detroit | Michigan | United States | 48201 |
19 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
20 | Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC | Kansas City | Missouri | United States | 64132 |
21 | Washington University Medical School | Saint Louis | Missouri | United States | 63110 |
22 | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | United States | 89169 |
23 | Hematology Oncology Associates Of Northern New Jersey | Morristown | New Jersey | United States | 07960 |
24 | Columbia University Medical Center | New York | New York | United States | 10032 |
25 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
26 | Messino Cancer Center | Asheville | North Carolina | United States | 28806 |
27 | Levine Cancer Institute | Charlotte | North Carolina | United States | 28204 |
28 | Wake Forest University School of Medicine | Winston-Salem | North Carolina | United States | 27157 |
29 | Oncology Hematology Care Inc | Cincinnati | Ohio | United States | 45236 |
30 | Willamette Valley Cancer Institute & Research Ctr. | Eugene | Oregon | United States | 97401 |
31 | Oregon Oncology Specialists | Salem | Oregon | United States | 97301 |
32 | UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | United States | 15213 |
33 | Sarah Cannon Research Institute SCRI | Nashville | Tennessee | United States | 37203 |
34 | Texas Oncology-Austin Midtown | Austin | Texas | United States | 78705 |
35 | Texas Oncology - Bedford | Bedford | Texas | United States | 76022 |
36 | University of Texas MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
37 | Texas Oncology - McAllen | McAllen | Texas | United States | 78503 |
38 | Texas Oncology - McKinney | McKinney | Texas | United States | 75071 |
39 | Texas Oncology - Sherman | Sherman | Texas | United States | 75090 |
40 | Texas Oncology - Tyler | Tyler | Texas | United States | 75702 |
41 | Virginia Cancer Specialists, PC | Gainesville | Virginia | United States | 20155 |
42 | University of Wisconsin Carbone Cancer Center | Madison | Wisconsin | United States | 53705 |
43 | Froedtert Memorial Lutheran Hospital | Milwaukee | Wisconsin | United States | 53226 |
44 | The St. George Hospital | Kogarah | New South Wales | Australia | 2217 |
45 | Flinders Medical Centre | Bedford Park | South Australia | Australia | 5042 |
46 | Royal Hobart Hospital | Hobart | Tasmania | Australia | 7000 |
47 | Andrew Lowe Cancer Centre | Geelong | Victoria | Australia | 3220 |
48 | Linear Clinical Research Ltd | Nedlands | Western Australia | Australia | WA6009 |
49 | Royal Perth Hospital | Perth | Western Australia | Australia | 6000 |
50 | Icon Cancer Care - The Wesley Medical Centre | Auchenflower | Australia | 4066 | |
51 | Ordensklinikum Linz GmbH Elisabethinen | Linz | Oberösterreich | Austria | 4020 |
52 | Uniklinikum Salzburg | Salzburg | Osterreich | Austria | 5020 |
53 | Universitair Ziekenhuis Gent | Gent | Belgium | 9000 | |
54 | Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg | Leuven | Belgium | 3000 | |
55 | BC Cancer Vancouver | Vancouver | British Columbia | Canada | V5Z 1H6 |
56 | Anhui Provincial Cancer Hospital | Hefei | Anhui | China | 233004 |
57 | Peking University First Hospital | Beijing | Beijing | China | 100034 |
58 | Peking University People's Hospital | Beijing | Beijing | China | 100044 |
59 | Beijing ChaoYang Hospital | Beijing | Beijing | China | 100141 |
60 | Peking University Third Hospital | Beijing | Beijing | China | 100191 |
61 | Beijing Cancer hospital | Haidian District | Beijing | China | 100142 |
62 | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong | China | 510060 |
63 | Southern Medical University Nanfang Hospital | Guangzhou | Guangdong | China | 510515 |
64 | Henan Cancer Hospital | Zhengzhou | Henan | China | 450008 |
65 | Wuhan Union Hospital | Wuhan | Hubei | China | 430022 |
66 | The First Affiliated Hospital of Soochow University | Suzhou | Jiangsu | China | 215066 |
67 | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi | China | 330006 |
68 | Shengjing Hospital of China Medical University | Shenyang | Liaoning | China | 110004 |
69 | West China Hospital of Sichuan University | Chengdu | Sichuan | China | 610041 |
70 | Tianjin Medical University Cancer Institute and Hospital | Tianjin | Tianjin | China | 300060 |
71 | Affiliated Tumor Hospital of Xinjiang Medical University | Urumqi | Xinjiang | China | 830002 |
72 | Zhejiang Cancer Hospital | Hangzhou | Zhejiang | China | 310022 |
73 | Chongqing Cancer Hospital | Chongqing | China | 400030 | |
74 | Blood Institute of the Chinese Academy of Medical science | Tianjin | China | 300020 | |
75 | Fakultni nemocnice Brno | Brno | Czechia | 62500 | |
76 | Fakultni nemocnice Hradec Kralove | Hradec Kralove | Czechia | 500 05 | |
77 | Aarhus Universitetshospital, Aarhus Sygehus | Aarhus N | Jutland | Denmark | DK-8200 |
78 | Odense Universitetshospital | Odense | Denmark | DK-5000 | |
79 | Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest | Bordeaux | Aquitaine | France | 33076 |
80 | Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen | Rouen | Seine-Maritime | France | 76038 |
81 | CHRU De Tours | Tours | Tours Cedex 9 | France | 37044 |
82 | Hopital Saint Vincent De Paul | Lille cedex | France | 59020 | |
83 | Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu | Nantes Cedex 1 | France | 44093 | |
84 | Centre hospitalier universitaire de Haut Leveque | Pessac Cedex | France | 33600 | |
85 | Centre Hospitalier Lyon Sud | Pierre Benite Cedex | France | 69495 | |
86 | Pole Regionalde Cancérologie(CHU de Poitiers) | Politiers | France | 86021 | |
87 | Chu De Nancy Hop D'Adultes De Brabois | Vandœuvre-lès-Nancy | France | 54500 | |
88 | Klinikum der Universität München Großhadern | München | Bayern | Germany | 81377 |
89 | St James's Hosptial | Dublin | Dublin 8 | Ireland | D08 NHY1 |
90 | Bnai Zion Medical Center | Haifa | Israel | 3339419 | |
91 | Hadassah Medical Center | Jerusalem | Israel | 9112001 | |
92 | Chaim Sheba Medical Center | Ramat Gan | Israel | ||
93 | Tel Aviv Sourasky Medical Center | Tel Aviv | Israel | 6423906 | |
94 | Presidio Ospedaliero Civile Santi Antonio e Biagio | Alessandria | AL | Italy | 15100 |
95 | Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori | Meldola | Emilia-Romagna | Italy | 47014 |
96 | Irccs Crob | Rionero in Vulture | Potenza | Italy | 85028 |
97 | IRCCS - AOU di Bologna | Bologna | Italy | 40138 | |
98 | IRCCS Ospedale Policlinico San Martino | Genova | Italy | 16132 | |
99 | Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte | Messina | Italy | 98158 | |
100 | Ospedale Vincenzo Cervello | Palermo | Italy | 90100 | |
101 | Ospedale Santa Maria delle Croci | Ravenna | Italy | 48020 | |
102 | Arcispedale Santa Maria Nuova | Reggio Emilia | Italy | 42123 | |
103 | Nagoya Medical Center | Nagoya | Aichi | Japan | 460-0001 |
104 | Nagoya City University Hospital | Nagoya | Aichi | Japan | 467-8602 |
105 | Hokkaido University Hospital | Sapporo | Hokkaido | Japan | 060-8648 |
106 | Kobe City Medical Center General Hospital | Kobe | Hyogo | Japan | 650-0047 |
107 | Kochi Medical School Hospital | Nankoku | Kochi | Japan | 783-8505 |
108 | Tohoku University Hospital | Sendai-shi | Miyagi | Japan | 980-8574 |
109 | Kindai University Hospital | Osaka Sayama-shi | Osaka | Japan | 589 8511 |
110 | Saitama Medical Center | Kawagoe | Saitama | Japan | 350-8550 |
111 | Japanese Foundation for Cancer Research | Koto | Tokyo | Japan | 135-8550 |
112 | NTT Medical Center Tokyo | Shinagawa-KU | Tokyo | Japan | 141-8625 |
113 | Chugoku Central Hospital | Hiroshima | Japan | 720-0001 | |
114 | Kumamoto University Hospital | Kumamoto | Japan | 860-8556 | |
115 | Kyoto Furitsu Medical University Hospital | Kyoto-shi | Japan | 602 8566 | |
116 | Okayama University Hospital | Okayama | Japan | 700-8558 | |
117 | Gachon University Gil Hospital | Namdong-gu | Incheon-gwangyeoksi [Incheon] | Korea, Republic of | 21565 |
118 | Kosin University Gospel Hospital | Busan | Seogu | Korea, Republic of | 49267 |
119 | Seoul National University Hospital | Seoul | Seoul, Korea | Korea, Republic of | 03080 |
120 | Severance Hospital, Yonsei University Health System | Seoul | Seoul-teukbyeolsi [Seoul] | Korea, Republic of | 03722 |
121 | Asan Medical Center | Seoul | Seoul-teukbyeolsi [Seoul] | Korea, Republic of | 05505 |
122 | Samsung Medical Center | Seoul | Seoul-teukbyeolsi [Seoul] | Korea, Republic of | 06351 |
123 | The Catholic University of Korea-Seoul St. Mary's Hospital | Seocho-Gu | Seoul | Korea, Republic of | 06591 |
124 | Ziekenhuisapotheek HagaZiekenhuis | Den Haag | Netherlands | 2545 AA | |
125 | Bravis Ziekenhuis | Roosendaal | Netherlands | 4708 AE | |
126 | Erasmus Medisch Centrum | Rotterdam | Netherlands | 3015 AA | |
127 | Middlemore Clinical Trials | Papatoetoe | Auckland | New Zealand | 2025 |
128 | Christchurch Hospital | Christchurch | New Zealand | 8011 | |
129 | Centrum Onkologii Ziemi Lubelskiej | Lublin | Lubelskie | Poland | 20-081 |
130 | Uniwersyteckie Centrum Kliniczne | Gdańsk | Pomorskie | Poland | 80-214 |
131 | Pratia MCM Krakow | Krakow | Poland | 30-510 | |
132 | IPOFG - Lisboa | Lisboa | Portugal | 1099-035 | |
133 | Champalimaud Foundation | Lisboa | Portugal | 1400-038 | |
134 | Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary" | Omsk | Omskaya Oblast' | Russian Federation | 644013 |
135 | GUZ of Moscow City Clinical Hospital n.a. S.P. Botkin | Moscow | Russian Federation | 125101 | |
136 | Federal State Budgetary Institution "Russian Scientific and Research Institute of Hematology and Transfusiology of Federal Medico-Biological Agency | Saint Petersburg | Russian Federation | 191024 | |
137 | State Medical University named after I.P. Pavlov | Saint-Petersburg | Russian Federation | 197022 | |
138 | Hospital Duran I Reynals | Hospitalet De Llobregat | Barcelona | Spain | 08908 |
139 | Hospital Universitari Vall d'Hebron | Barcelona | Spain | 08035 | |
140 | Hospital General Universitario Gregorio Marañon | Madrid | Spain | 28007 | |
141 | Hospital Infanta Leonor | Madrid | Spain | 28031 | |
142 | Hospital Universitario Fundación Jiménez Díaz | Madrid | Spain | 28040 | |
143 | Hospital Universitario 12 de Octubre | Madrid | Spain | 28041 | |
144 | Kantonsspital Luzern | Luzern 16 | Luzern | Switzerland | 6000 |
145 | Ospedale Regionale Bellinzona e Valli | Bellinzona | Switzerland | CH-6500 | |
146 | Tri-Service General Hospital | Taipei City | Taipei | Taiwan | 114 |
147 | Chang Gung Memorial Hospital - Chiayi | Chiayi County | Taiwan | 61363 | |
148 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | Taiwan | 80756 | |
149 | China Medical University Hospital | Taichung | Taiwan | 40447 | |
150 | National Cheng-Kung Uni. Hosp. | Tainan | Taiwan | 704 | |
151 | National Taiwan University Hospital | Taipei | Taiwan | 10002 | |
152 | Taipei Veterans General Hospital | Taipei | Taiwan | 11217 | |
153 | Chang Gung Memorial Hospital - Linkou | Taoyuan City | Taiwan | 333 | |
154 | Aberdeen Royal Infirmary | Aberdeen | Aberdeen City | United Kingdom | AB25 2ZN |
155 | Churchill Hospital | Headington | Oxford | United Kingdom | OX3 7LE |
156 | GenesisCare Cambridge | Newmarket | United Kingdom | CB8 7XN | |
157 | City Hospital, Nottingham University Hospitals | Nottingham | United Kingdom | NG5 1PB | |
158 | Derriford Hospital | Plymouth | United Kingdom | Pl6 8DH | |
159 | New Cross Hospital | Wolverhampton | United Kingdom | WV10 0QP |
Sponsors and Collaborators
- Loxo Oncology, Inc.
- Eli Lilly and Company
Investigators
- Study Director: Patient Advocacy, Loxo Oncology, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LOXO-BTK-20019
- J2N-OX-JZNM